Suchitra Joshi

Dr. Suchitra Joshi


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Brain Research
Verified
Journal Article
Closed access
SJSuchitra Joshi
Suchitra Joshi
JKJaideep Kapur
Jaideep Kapur

1 January 2021 in Neuroscience Letters
Verified
Journal Article
Closed access
JKJaideep Kapur
Jaideep Kapur
SJSuchitra Joshi
Suchitra Joshi

1 November 2019 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
NANadia Adotevi
Nadia Adotevi
ELEwa Lewczuk
Ewa Lewczuk
HSHuayu Sun
Huayu Sun
SJSuchitra Joshi
Suchitra Joshi
NDNatalia Dabrowska
Natalia Dabrowska
JKJaideep Kapur
Jaideep Kapur

16 October 2020 in Epilepsia
Verified
Journal Article
Closed access
PDF file
TSTanveer Singh
Tanveer Singh
SJSuchitra Joshi
Suchitra Joshi
JWJohn M. Williamson
John M. Williamson
JKJaideep Kapur
Jaideep Kapur

6 December 2017 in Epilepsia
Verified
Journal Article
Closed access
PDF file
ELEwa Lewczuk
Ewa Lewczuk
SJSuchitra Joshi
Suchitra Joshi
JWJohn Williamson
John Williamson
MPMouna Penmetsa
Mouna Penmetsa
SSSarah Shan
Sarah Shan
JKJaideep Kapur
Jaideep Kapur

1 July 2019 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
PDF file
SSShinnosuke Shiono
Shinnosuke Shiono
JWJohn Williamson
John Williamson
JKJaideep Kapur
Jaideep Kapur
SJSuchitra Joshi
Suchitra Joshi
Objective: Progesterone is a potent neuromodulator that exerts effects on the brain through neurosteroids, progesterone receptors (PRs), and other molecules. Whether PR activation regulates seizures is not known. We determined whether PR activation increased seizure susceptibility.Methods: Adult female rats that developed epilepsy following lithium‐pilocarpine‐induced status epilepticus (SE) were used. Seizures were recorded by continuous‐video EEG and read by an individual blinded to the treatment of the animals. The animals were treated for a week with progesterone (50 mg/kg per day), and the effect of progesterone withdrawal on seizure frequency was assessed during the subsequent week. During the week of progesterone treatment, the animals were treated with PR antagonist RU‐486 (10 mg/kg per day) or a vehicle control, which was administered 30 min before progesterone. In another set of animals, we determined the effect of the PR agonist Nestorone (3 mg/kg per day) on seizure frequency. The animals were treated with Nestorone or vehicle for a week, and seizure frequencies at baseline and during the treatment week were compared.Results: Progesterone withdrawal induced twofold increase in seizures in 57% of animals (n = 14). RU‐486 treatment in combination with progesterone, prevented this increase, and a smaller fraction of animals (17%) experienced withdrawal seizures (n = 13). The specific activation of PRs by Nestorone also increased the seizure frequency. Forty‐six percent (n = 14) of Nestorone‐treated animals experienced at least a 50% increase in seizures compared to only 9% of the vehicle‐treated animals (n = 11).Interpretation: PR activation increased seizure frequency in epileptic animals. Thus, PRs may be novel targets for treating catamenial epilepsy.